Trending NewsTrending NewsNYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis $238.17 +5.09 (+2.18%) Closing price 11/19/2026Extended Trading$240.25 +2.08 (+0.87%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Glaukos Stock (NYSE:GKOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Glaukos alerts:Sign Up Key Stats Today's Range$231.61▼$239.3450-Day Range$153.63▼$248.0052-Week Range$93.78▼$255.18Volume744,956 shsAverage Volume1.92 million shsMarket Capitalization$14.10 billionP/E RatioN/ADividend YieldN/APrice Target$218.00Consensus RatingModerate Buy Company Overview Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea. Glaukos was founded in 1998 and helped establish the MIGS category as an alternative to traditional glaucoma surgery. Based in Aliso Viejo, California, Glaukos serves eye-care professionals and patients in the United States and internationally. Its products are distributed in multiple markets, with availability varying by country and regulatory approval.AI Generated. May Contain Errors. Read More Glaukos Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreGKOS MarketRank™: 2.75821917808 of 5 starsGlaukos scored higher than 55% of companies evaluated by MarketBeat, and ranked 412th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 13 buy ratings, 1 hold rating, and 1 sell rating.Downside RiskGlaukos has a consensus price target of $218.00, representing about 8.5% downside from its current price of $238.17.Amount of Analyst CoverageGlaukos has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Glaukos' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth202.00% Earnings GrowthEarnings for Glaukos are expected to grow by 202.00% in the coming year, from $0.50 to $1.51 per share.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 19.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.05% of the float of Glaukos has been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 2.85, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Glaukos has recently increased by 3.24%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.88 News SentimentGlaukos has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Glaukos this week, compared to 5 articles on an average week.Search Interest10 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows7 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,386,705.00 in company stock.Percentage Held by Insiders5.90% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Glaukos' insider trading history. Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GKOS Stock News HeadlinesGlaukos (NYSE:GKOS) Stock: Insider Joseph Gilliam Sells 861 SharesNovember 19 at 7:07 AM | insidertrades.comGlaukos (GKOS) Stock May Be 33% Below Fair Value On Cash FlowNovember 18 at 8:30 PM | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 19 at 1:00 AM | Behind the Markets (Ad)Glaukos (GKOS) Has Investors Asking A Bigger QuestionNovember 18 at 3:29 PM | finance.yahoo.comGlaukos (NYSE:GKOS) Stock Price Expected to Rise, BTIG Research Analyst SaysNovember 18 at 2:13 AM | americanbankingnews.comGlaukos Insider Sold Shares Worth $11,063,782, According to a Recent SEC FilingNovember 17 at 8:19 AM | marketscreener.comMGlaukos (NYSE:GKOS) COO Sells $11,063,955.44 in StockNovember 17 at 4:07 AM | insidertrades.comGlaukos (NYSE:GKOS) Stock: Insider Gilbert Kliman Sells 2,500 SharesNovember 6, 2026 | insidertrades.comSee More Headlines GKOS Stock Analysis - Frequently Asked Questions How have GKOS shares performed this year? Glaukos' stock was trading at $112.80 at the beginning of 2026. Since then, GKOS stock has increased by 111.1% and is now trading at $238.17. How were Glaukos' earnings last quarter? Glaukos Corporation (NYSE:GKOS) posted its quarterly earnings results on Wednesday, October, 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.57. The firm's revenue for the quarter was up 58.0% on a year-over-year basis. Read the conference call transcript. When did Glaukos IPO? Glaukos (GKOS) raised $99 million in an initial public offering on Thursday, June 25th 2015. The company issued 6,000,000 shares at $16.00-$17.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Top institutional investors of Glaukos include State Street Corp (3.91%), Goldman Sachs Group Inc. (1.73%), William Blair Investment Management LLC (1.10%) and Anomaly Capital Management LP (0.88%). Insiders that own company stock include Thomas William Burns, Tomas Navratil, Joseph E Gilliam, Alex R Thurman, Marc Stapley, Gilbert H Kliman, Mark J Foley, Leana Wen and Aimee S Weisner. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Taiwan Semiconductor Manufacturing (TSM), Tesla (TSLA), Micron Technology (MU) and NeoGenomics (NEO). Company Calendar Last Earnings10/28/2026Today11/19/202638th Annual Healthcare Conference12/01/2026Citi Annual Global Healthcare Conference 202612/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GKOS's financial health is in the Green zone, according to TradeSmith. GKOS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:GKOS CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees1,094Year Founded1998Price Target and Rating Average Price Target for Glaukos$218.00 High Price Target$255.00 Low Price Target$138.00 Potential Upside/Downside-8.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$187.69 million Net Margins-24.60% Pretax Margin-25.28% Return on Equity-0.97% Return on Assets-0.71% Debt Debt-to-Equity Ratio0.09 Current Ratio4.57 Quick Ratio4.09 Sales & Book Value Annual Sales$507.44 million Price / Sales27.79 Cash FlowN/A Price / Cash FlowN/A Book Value$12.12 per share Price / Book19.65Miscellaneous Outstanding Shares59,200,000Free Float55,704,000Market Cap$14.10 billion OptionableOptionable Beta0.68 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:GKOS) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.